Navigation Links
Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
Date:2/5/2008

proval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.


'/>"/>
SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , 17 de septiembre de 2014 /PRNewswire/ ... principal proveedor mundial de soluciones logísticas avanzadas ... de la vida, anunció hoy la contratación ... global con sede en Rótterdam, Países Bajos, ... clientes Europa en rápido crecimiento. Según los ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... The Alliance for Clinical ... non-profit collaborative building a global system to enhance ... announced Phase 3 of its Site Accreditation and ... H. Kalali, Vice-President, Global Head, Neuroscience Center of ... and Quality Integration (CQI) Consulting will lead the ...
(Date:9/16/2014)... energy from jaw movements has been created by a ... that the device can generate electricity from eating, chewing ... or wearable electronic devices, such as hearing aids, cochlear ... first results of the device,s performance have been published ... Materials and Structures . , Jaw movements have proved ...
Breaking Biology Technology:Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2
... MO BIO Laboratories, Inc., a leader in nucleic ... of an innovative new product for gel electrophoresis, Dye ... time-consuming step in the gel loading process, remove the ... tip waste. (Photo: http://photos.prnewswire.com/prnh/20110223/LA52919 ) ...
... announces that a new market research report is ... Biotechnology Reagents Industry http://www.reportlinker.com/p098414/Global-Biotechnology-Reagents-Industry.html ... worldwide markets for Biotechnology Reagents in US$ Million ... DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, Flow Cytometry Reagents, ...
... 23, 2011 Ingenuity® Systems, a leading provider ... researchers, today announced a research collaboration with Covance ... (NGS) data analysis. Covance Genomics Laboratory, a leading ... and development industry, and Ingenuity will work together ...
Cached Biology Technology:MO BIO Laboratories, Inc. Launches Dye Dots™ Dry Gel Loading Dye 2Reportlinker Adds Global Biotechnology Reagents Industry 2Ingenuity Systems and Covance Collaborate to Support Next-Generation Sequencing Research 2
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
(Date:9/17/2014)... MSSA could be curbed by coating hospital surfaces ... of shark skin, according to research published in ... Infection Control . , The study modelled how ... disease bacteria through touching, sneezes or spillages. The ... formulated to resemble shark skin. The study showed ...
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
Breaking Biology News(10 mins):Coral growth rate plummets in 30-year comparison 2Sharks' skin has teeth in the fight against hospital superbugs 2Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... in the field of life in extreme environments research ... offices in Cambridge (UK) to officially kick off the ... in Extreme Environments). , Life in Extreme Environments is ... considerable expertise but a relatively fragmented research infrastructure. The ...
... Care Congress is the premier forum for health care ... to network with key leaders. The 2008 Congress will ... largest employers, hospitals, health systems, health plans, pharmaceutical and ... many highlights, the Presidential Health Care Agenda, will feature ...
... Coral reefs could be dying out because of changes to ... from the direct rise in temperature caused by global warming, ... the Society for General Microbiologys 162nd meeting being held this ... are currently balanced on a climate change knife edge. Corals ...
Cached Biology News:5th Annual World Health Care Congress April 21-23, Washington, D.C. 2Coral reefs and climate change: Microbes could be the key to coral death 2Coral reefs and climate change: Microbes could be the key to coral death 3
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: